Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert T. Connelly
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Beta
- 1.88
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -13.58
Financials
Revenue
$0.00-100.0%Net Income
$-8.22MEBITDA
$-12.91MFree Cash Flow
$-8.16MEPS (diluted)
$-0.43Shares Outstanding (diluted)
19.24M+552.7%Operating Expenses
$10.43MCash & Debt
$23.48MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-39.57M | $-2.58 |
| 2024 | $0.00 | $-51.90M | $-4.25 |
| 2023 | $0.00 | $-35.20M | $-6.96 |
| 2022 | $0.00 | $-28.21M | $-9.10 |
| 2021 | $28.31M | $-26.40M | $-19.32 |
| 2020 | $2.88M | $-80.11M | $-1.93 |
| 2019 | $1.49M | $-40.66M | $-1.50 |
| 2018 | $4.03M | $-20.02M | $-6.79 |
| 2013 | $6.58M | $632.2K | $103.31 |
| 2012 | $7.30M | $307.3K | $50.21 |
Valuation
ELTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·6h ago·Neutral
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA.
View source ↗
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.52 per share
Typical surprise -4.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.43 vs $-0.54beat
- Mon, May 11$-0.65 vs $-0.49miss
- Thu, Mar 12$-0.49 vs $-0.47miss
- Thu, Nov 13$-0.60 vs $-0.62beat
- Thu, Aug 7$-0.66 vs $-0.69beat
- Tue, May 13$-0.87 vs $-0.67miss
Estimates and results for ELTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ELTX officers and directors.
- Bought
- $28.3m
- Sold
- —
6 trades
0 trades
- Chudnovsky Yekaterinabought
- Venkatesan Jaybought
- Venkatesan Jaybought
- Chudnovsky Yekaterinabought
- Chudnovsky Yekaterinabought
- Chudnovsky Yekaterinabought
48 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.